FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1601605893> ?p ?o ?g. }

• W1601605893 endingPage "82" @default.
• W1601605893 startingPage "277" @default.
• W1601605893 abstract "The pharmacodynamics of doxorubicin in human prostate tumors were studied using histocultures of radical prostatectomy specimens. Drug treatment lasted 96 h. The antiproliferative effect was measured by the inhibition of DNA precursor ([3H]thymidine) incorporation, and the cytotoxic effect was measured by monitoring cells with fragmented DNA, as indicated by the terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay. The average [3H]thymidine labeling index in 17 tumors was 39% (range, 20-56%). The antiproliferative and cytotoxic effects were concentration dependent and reached 100% at 6 and 17 microM doxorubicin. The cytotoxic concentrations were significantly higher than the antiproliferative concentrations, indicating that prostate tumors were more sensitive to the antiproliferative effect than they were to the cytotoxic effect of doxorubicin. The antiproliferative effect was inversely correlated with patient's age (P < 0.02) and weakly correlated with LI and Gleason grade (P = 0.07 and 0.06, respectively), but it was not correlated with clinical stage, prostate-specific antigen secretion, or race of patients (P > 0.12). In contrast, the cytotoxic effect was positively correlated with Gleason grade (P < 0.05) and weakly correlated with stage (P < 0.08), but it was not correlated with the other parameters (P > 0.18). The opposite correlations between the two effects with tumor grade suggest that the two effects are not coupled. A comparison of the drug concentrations required to produce 50% antiproliferative (0.06 microM) and cytotoxic (2 microM) effects and the literature data on plasma drug concentrations derived from systemic treatment suggest that there are minimal drug effects at the clinically achievable drug concentrations and that regional delivery of doxorubicin to the prostate may be necessary to provide adequate concentrations to produce antiproliferative and cytotoxic effects." @default.
• W1601605893 created "2016-06-24" @default.
• W1601605893 creator A5024593607 @default.
• W1601605893 creator A5077645346 @default.
• W1601605893 creator A5085031128 @default.
• W1601605893 date "1998-02-01" @default.
• W1601605893 modified "2023-09-26" @default.
• W1601605893 title "Pharmacodynamics of doxorubicin in human prostate tumors." @default.
• W1601605893 cites W1882622037 @default.
• W1601605893 cites W1976570855 @default.
• W1601605893 cites W1982230933 @default.
• W1601605893 cites W1983440388 @default.
• W1601605893 cites W2013031942 @default.
• W1601605893 cites W2015228718 @default.
• W1601605893 cites W2021292361 @default.
• W1601605893 cites W2023067707 @default.
• W1601605893 cites W2023125141 @default.
• W1601605893 cites W2056626972 @default.
• W1601605893 cites W2063988594 @default.
• W1601605893 cites W2090265676 @default.
• W1601605893 cites W2119912961 @default.
• W1601605893 cites W221956105 @default.
• W1601605893 cites W2425791025 @default.
• W1601605893 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9516911" @default.
• W1601605893 hasPublicationYear "1998" @default.
• W1601605893 type Work @default.
• W1601605893 sameAs 1601605893 @default.
• W1601605893 citedByCount "8" @default.
• W1601605893 countsByYear W16016058932015 @default.
• W1601605893 crossrefType "journal-article" @default.
• W1601605893 hasAuthorship W1601605893A5024593607 @default.
• W1601605893 hasAuthorship W1601605893A5077645346 @default.
• W1601605893 hasAuthorship W1601605893A5085031128 @default.
• W1601605893 hasConcept C111113717 @default.
• W1601605893 hasConcept C112705442 @default.
• W1601605893 hasConcept C121608353 @default.
• W1601605893 hasConcept C126322002 @default.
• W1601605893 hasConcept C154317977 @default.
• W1601605893 hasConcept C185592680 @default.
• W1601605893 hasConcept C202751555 @default.
• W1601605893 hasConcept C2776235491 @default.
• W1601605893 hasConcept C2776694085 @default.
• W1601605893 hasConcept C2781303535 @default.
• W1601605893 hasConcept C55493867 @default.
• W1601605893 hasConcept C71924100 @default.
• W1601605893 hasConcept C98274493 @default.
• W1601605893 hasConceptScore W1601605893C111113717 @default.
• W1601605893 hasConceptScore W1601605893C112705442 @default.
• W1601605893 hasConceptScore W1601605893C121608353 @default.
• W1601605893 hasConceptScore W1601605893C126322002 @default.
• W1601605893 hasConceptScore W1601605893C154317977 @default.
• W1601605893 hasConceptScore W1601605893C185592680 @default.
• W1601605893 hasConceptScore W1601605893C202751555 @default.
• W1601605893 hasConceptScore W1601605893C2776235491 @default.
• W1601605893 hasConceptScore W1601605893C2776694085 @default.
• W1601605893 hasConceptScore W1601605893C2781303535 @default.
• W1601605893 hasConceptScore W1601605893C55493867 @default.
• W1601605893 hasConceptScore W1601605893C71924100 @default.
• W1601605893 hasConceptScore W1601605893C98274493 @default.
• W1601605893 hasIssue "2" @default.
• W1601605893 hasLocation W16016058931 @default.
• W1601605893 hasOpenAccess W1601605893 @default.
• W1601605893 hasPrimaryLocation W16016058931 @default.
• W1601605893 hasRelatedWork W2019493845 @default.
• W1601605893 hasRelatedWork W2025106411 @default.
• W1601605893 hasRelatedWork W2044590347 @default.
• W1601605893 hasRelatedWork W2048424737 @default.
• W1601605893 hasRelatedWork W2074544404 @default.
• W1601605893 hasRelatedWork W2099235218 @default.
• W1601605893 hasRelatedWork W2163514148 @default.
• W1601605893 hasRelatedWork W2391597003 @default.
• W1601605893 hasRelatedWork W2411764570 @default.
• W1601605893 hasRelatedWork W2460673741 @default.
• W1601605893 hasVolume "4" @default.
• W1601605893 isParatext "false" @default.
• W1601605893 isRetracted "false" @default.
• W1601605893 magId "1601605893" @default.
• W1601605893 workType "article" @default.